457 related articles for article (PubMed ID: 29046115)
1. Bone and the Immune System.
Weitzmann MN
Toxicol Pathol; 2017 Oct; 45(7):911-924. PubMed ID: 29046115
[TBL] [Abstract][Full Text] [Related]
2. Enhanced immunoprotective effects by anti-IL-17 antibody translates to improved skeletal parameters under estrogen deficiency compared with anti-RANKL and anti-TNF-α antibodies.
Tyagi AM; Mansoori MN; Srivastava K; Khan MP; Kureel J; Dixit M; Shukla P; Trivedi R; Chattopadhyay N; Singh D
J Bone Miner Res; 2014 Sep; 29(9):1981-92. PubMed ID: 24677326
[TBL] [Abstract][Full Text] [Related]
3. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis.
Romas E; Gillespie MT; Martin TJ
Bone; 2002 Feb; 30(2):340-6. PubMed ID: 11856640
[TBL] [Abstract][Full Text] [Related]
4. The relationship between osteoclastogenic and anti-osteoclastogenic pro-inflammatory cytokines differs in human osteoporotic and osteoarthritic bone tissues.
Zupan J; Komadina R; Marc J
J Biomed Sci; 2012 Mar; 19(1):28. PubMed ID: 22380539
[TBL] [Abstract][Full Text] [Related]
5. Bone Remodeling and the Role of TRAF3 in Osteoclastic Bone Resorption.
Boyce BF; Li J; Xing L; Yao Z
Front Immunol; 2018; 9():2263. PubMed ID: 30323820
[TBL] [Abstract][Full Text] [Related]
6. New insights into osteoclastogenic signaling mechanisms.
Nakashima T; Hayashi M; Takayanagi H
Trends Endocrinol Metab; 2012 Nov; 23(11):582-90. PubMed ID: 22705116
[TBL] [Abstract][Full Text] [Related]
7. Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review).
Liu W; Zhang X
Mol Med Rep; 2015 May; 11(5):3212-8. PubMed ID: 25572286
[TBL] [Abstract][Full Text] [Related]
8. Dysregulated B cell expression of RANKL and OPG correlates with loss of bone mineral density in HIV infection.
Titanji K; Vunnava A; Sheth AN; Delille C; Lennox JL; Sanford SE; Foster A; Knezevic A; Easley KA; Weitzmann MN; Ofotokun I
PLoS Pathog; 2014 Oct; 10(10):e1004497. PubMed ID: 25393853
[TBL] [Abstract][Full Text] [Related]
9. Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology.
Hofbauer LC; Heufelder AE
J Mol Med (Berl); 2001 Jun; 79(5-6):243-53. PubMed ID: 11485016
[TBL] [Abstract][Full Text] [Related]
10. Bone turnover, osteoprotegerin/RANKL and inflammation with antiretroviral initiation: tenofovir versus non-tenofovir regimens.
Brown TT; Ross AC; Storer N; Labbato D; McComsey GA
Antivir Ther; 2011; 16(7):1063-72. PubMed ID: 22024522
[TBL] [Abstract][Full Text] [Related]
11. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/RANK ligand signaling?
Van Bezooijen RL; Papapoulos SE; Löwik CW
Bone; 2001 Apr; 28(4):378-86. PubMed ID: 11336918
[TBL] [Abstract][Full Text] [Related]
12. Disruption of PTH receptor 1 in T cells protects against PTH-induced bone loss.
Tawfeek H; Bedi B; Li JY; Adams J; Kobayashi T; Weitzmann MN; Kronenberg HM; Pacifici R
PLoS One; 2010 Aug; 5(8):e12290. PubMed ID: 20808842
[TBL] [Abstract][Full Text] [Related]
13. Parathyroid Diseases and T Cells.
Neale Weitzmann M; Pacifici R
Curr Osteoporos Rep; 2017 Jun; 15(3):135-141. PubMed ID: 28421466
[TBL] [Abstract][Full Text] [Related]
14. Skeletal changes in osteoprotegerin and receptor activator of nuclear factor-kappab ligand mRNA levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism.
Stilgren LS; Rettmer E; Eriksen EF; Hegedüs L; Beck-Nielsen H; Abrahamsen B
Bone; 2004 Jul; 35(1):256-65. PubMed ID: 15207766
[TBL] [Abstract][Full Text] [Related]
15. Porphyromonas gingivalis-derived lysine gingipain enhances osteoclast differentiation induced by tumor necrosis factor-α and interleukin-1β but suppresses that by interleukin-17A: importance of proteolytic degradation of osteoprotegerin by lysine gingipain.
Akiyama T; Miyamoto Y; Yoshimura K; Yamada A; Takami M; Suzawa T; Hoshino M; Imamura T; Akiyama C; Yasuhara R; Mishima K; Maruyama T; Kohda C; Tanaka K; Potempa J; Yasuda H; Baba K; Kamijo R
J Biol Chem; 2014 May; 289(22):15621-30. PubMed ID: 24755218
[TBL] [Abstract][Full Text] [Related]
16. [The OPG/RANKL/RANK system and bone resorptive disease].
Liu JZ; Ji ZL; Chen SM
Sheng Wu Gong Cheng Xue Bao; 2003 Nov; 19(6):655-60. PubMed ID: 15971575
[TBL] [Abstract][Full Text] [Related]
17. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover.
Cheng CH; Chen LR; Chen KH
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163300
[TBL] [Abstract][Full Text] [Related]
18. RANKL targeted peptides inhibit osteoclastogenesis and attenuate adjuvant induced arthritis by inhibiting NF-κB activation and down regulating inflammatory cytokines.
Naidu VG; Dinesh Babu KR; Thwin MM; Satish RL; Kumar PV; Gopalakrishnakone P
Chem Biol Interact; 2013 Apr; 203(2):467-79. PubMed ID: 23333834
[TBL] [Abstract][Full Text] [Related]
19. Crosstalk between bone niche and immune system: osteoimmunology signaling as a potential target for cancer treatment.
Criscitiello C; Viale G; Gelao L; Esposito A; De Laurentiis M; De Placido S; Santangelo M; Goldhirsch A; Curigliano G
Cancer Treat Rev; 2015 Feb; 41(2):61-8. PubMed ID: 25499997
[TBL] [Abstract][Full Text] [Related]
20. IL-7 induces bone loss in vivo by induction of receptor activator of nuclear factor kappa B ligand and tumor necrosis factor alpha from T cells.
Toraldo G; Roggia C; Qian WP; Pacifici R; Weitzmann MN
Proc Natl Acad Sci U S A; 2003 Jan; 100(1):125-30. PubMed ID: 12490655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
